Quel est le prix pour Clover Biopharmaceuticals, Ltd. (2197)

Le prix pour Clover Biopharmaceuticals, Ltd. (2197) est $0.25841098

Quelle est la capitalisation boursière pour Clover Biopharmaceuticals, Ltd. (2197)

La capitalisation boursière pour Clover Biopharmaceuticals, Ltd. (2197) est $335.38M

Clover Biopharmaceuticals, Ltd. (2197) Prix et Capitalisation Boursière

Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.

Prix pour 2197	L’actif B	La capitalisation boursière de B	Résultats
$4,092.15 $335.38M	NVDA	$5.311T	+1,583,481.12%
$3,673.59 $335.38M	AAPL	$4.768T	+1,421,509.44%
$3,111.78 $335.38M	GOOG	$4.039T	+1,204,099.16%
$2,868.75 $335.38M	MSFT	$3.723T	+1,110,050.81%
$2,108.29 $335.38M	AMZN	$2.736T	+815,767.96%

Prix pour 2197

L’actif B

La capitalisation boursière de B

Résultats

$4,092.15 $335.38M